Calcium Release Deficiency SyndromeCRDS RegistryNCT06508164
International CRDS Registry
An observational study of Calcium Release Deficiency Syndrome, run by Population Health Research Institute at 22 sites in 8 countries.
Trial summary
Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Calcium Release Deficiency Syndrome
- How many people
- 500 participants
- Where
- 22 sitesin 8 countries
- Study dates
- 21 Nov 2024to 31 Dec 2050
- How long will I take part?
- 26 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The registry will enrol 3 separate cohorts. The primary cohort consists of CRDS cases. A CRDS case is defined as an individual that possesses a rare RYR2 variant proven to be loss-of-function on in vitro analysis. A second cohort consists of individuals that possess a rare RYR2 truncating variant or large copy number variant. The third cohort involves individuals suspected of having CRDS, however in vitro analysis revealed that their rare RYR2 variant did not impact function.
Who may be able to join
- Presence of a rare* RYR2 variant that is characterized to be loss-of-function based on in vitro testing#
- RYR2 Truncating and Large CNV Cohort
- Presence of a rare* RYR2 truncating variant and/or large copy number variant involving the RYR2 gene.
- Carriers of a Non-Functional RYR2 variant
- Presence of a rare* RYR2 variant that is characterized to be neither loss- nor gain-of-function based on in vitro testing#
- rare defined as gnomAD prevalence < 0.1%
- #RYR2 in vitro functional testing will be performed in the laboratory of Dr. Wayne Chen (University of Calgary)
Who cannot join
None listed.
Trial locations and contacts
22 sites in 8 countries. Contact the study team or a site near you to ask about taking part.
22 sites in 8 countries
Canada9 sites, 9 recruiting
- Recruiting
University of Calgary
Calgary, Alberta, T2N 1N4
Project Manager, 905-521-2100, crds@phri.ca
Erkan Ilhan, MD
- Recruiting
Alberta Health Services
Edmonton, Alberta, T6G 2C8
Project Manager, 905-521-2100, crds@phri.ca
Joseph Atallah, MD CM, MSc
- Recruiting
Hamilton General Hospital
Hamilton, Ontario, L8L 2X2
905-521-2100, crds@phri.ca
Jason D Roberts, MD MAS
- Recruiting
London Health Sciences Centre - University Hospital
London, Ontario, N6A 5A5
Project Manager, 905-521-2100, crds@phri.ca
Habib R Khan, MD
- Recruiting
Montréal Heart Institute
Montreal, Quebec, H1T 1C8
Project Manager, 905-521-2100, crds@phri.ca
Rafik Tadros, MD PhD
- Recruiting
Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7
Project Manager, 905-521-2100, crds@phri.ca
Simon Hansom, MD
- Recruiting
Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval
Québec, Quebec
905-521-2100, crds@phri.ca
Christian Steinberg, MD
- Recruiting
Children's & Women's Health Centre of British Columbia
Vancouver, British Columbia, V6H 3N1
Project Manager, 905-521-2100, crds@phri.ca
Shubhayan Sanatani, MD
- Recruiting
The University of British Columbia
Vancouver, British Columbia, V6T 1Z3
Project Manager, 905-521-2100, crds@phri.ca
Thomas M Roston, MD
United States4 sites, 4 recruiting
- Recruiting
Duke University
Durham, North Carolina, 27710
Project Manager, 905-521-2100, crds@phri.ca
Andrew Landstrom, MD, PhD
- Recruiting
Inova Health Care Services
Fairfax, Virginia, 22031
Project Manager, 905-521-2100, crds@phri.ca
Robert Przybylski, MD
- Recruiting
Mayo Clinic
Rochester, Minnesota, 55905
Project Manager, 905-521-2100, crds@phri.ca
John Giudicessi, MD, PhD
- Recruiting
University of California
San Francisco, California, 94143
Project Manager, 905-521-2100, crds@phri.ca
Vasanth Vedantham, MD, PhD
Belgium2 sites, 2 recruiting
- Recruiting
Universitair Ziekenhuis Brussel
Brussels, 1090
Project Manager, 905-521-2100, crds@phri.ca
Luigi Pannone, MD
- Recruiting
Antwerp University Hospital
Edegem, Antwerp, 2650
Project Manager, 905-521-2100, crds@phri.ca
Johan Saenen, MD, PhD
Denmark2 sites, 2 recruiting
- Recruiting
Aarhus University Hospital
Aarhus, DK-8200 N
Project Manager, 905-521-2100, crds@phri.ca
Henrik Jensen, MD
- Recruiting
Rigshospitalet
Copenhagen, The Capital Region of Denmark, 2100
Project Manager, 905-521-2100, crds@phri.ca
Jacob Tfelt-Hansen, MD, DMSc
United Kingdom2 sites, 2 recruiting
- Recruiting
City St George's, University of London
London, EC1V 0HB
Project Manager, 905-521-2100, crds@phri.ca
Mark Specterman, MBBS, MRCP, PhD
- Recruiting
Oxford University Hospitals
Oxford, Oxfordshire, 0X3 9DU
Project Manager, 905-521-2100, crds@phri.ca
Julian Ormerod, BM, Bch, FRCP
Australia1 site, 1 recruiting
- Recruiting
Garvan Institute of Medical Research
Darlinghurst, New South Wales, 2010
Project Manager, 905-521-2100, crds@phri.ca
Jodie Ingles, PhD, MPH
France1 site, 1 recruiting
- Recruiting
CHU de Bordeaux
Bordeaux, New Aquitaine, 33404
Project Manager, 905-521-2100, crds@phri.ca
Frédéric Sacher, MD
Israel1 site, 1 recruiting
- Recruiting
Shaare Zedek Medical Center
Jerusalem, 9103102
Project Manager, 905-521-2100, crds@phri.ca
Ziv Dadon, MD
About this study
Official title: International Calcium Release Deficiency Syndrome Registry
Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.
Read the detailed description
Calcium Release Deficiency Syndrome (CRDS) is a recently discovered inherited arrhythmia syndrome that predisposes to malignant ventricular arrhythmias and sudden cardiac death (SCD). The underlying genetic culprit of CRDS is RYR2, which encodes the cardiac ryanodine receptor. In contrast to Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), which stems from pathogenic RYR2 gain-of-function, CRDS manifests secondary to RyR2 loss-of-function. Enrolment into the CRDS registry requires that the putative disease causing RYR2 variant is confirmed to result in a loss-of-function on in vitro functional analysis. Individuals possessing an RYR2 truncating variant or large copy number variant will be eligible for enrolment into a second registry arm. Patients with a suspected CRDS diagnosis whose RYR2 variant is found not to impact function will be entered into a control arm of the registry.
Given its recent discovery, our understanding of CRDS remains in its infancy. The International CRDS registry has been designed to facilitate evaluation of large numbers of CRDS patients and enable robust insights to hopefully improve management of affected patients and families.
- Conditions
- Calcium Release Deficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| CRDS | Possesses a rare RYR2 variant characterized to be loss-of-function based on in vitro testing consistent with a CRDS diagnosis | |
| Carrier of an RYR2 truncating variant or large copy number variant | Possesses a rare RYR2 truncating variant and/or large copy number variant involving the RYR2 gene. | |
| Carrier of a non-functional RYR2 rare variant | Possesses a rare RYR2 variant that is NOT loss-of-function based on in vitro testing and has a clinical phenotype that was considered compatible with CRDS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Malignant Ventricular Arrhythmia
Composite of malignant syncope, ICD shock, cardiac arrest, and sudden cardiac death
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2024
- Study start21 Nov 2024
- Primary completion31 Dec 2050 (estimated)
- Study completion31 Dec 2050 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Calcium Release Deficiency SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 26 Years
Sponsor and investigators
- Lead sponsor
- Population Health Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Responsible party
- Sponsor
- Investigators
- Thomas M Roston, MD, PhD, Study chair, University of British ColumbiaJason D Roberts, MD MAS, Principal investigator, McMaster UniversitySR Wayne Chen, PhD, Principal investigator, University of Calgary
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06508164
- Sponsor's protocol ID
- 16861
- Acronym
- CRDS Registry
- Status last verified
- Jun 2026
- First submitted
- 8 Jul 2024
- Last updated
- 28 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sun B, Yao J, Ni M, Wei J, Zhong X, Guo W, Zhang L, Wang R, Belke D, Chen YX, Lieve KVV, Broendberg AK, Roston TM, Blankoff I, Kammeraad JA, von Alvensleben JC, Lazarte J, Vallmitjana A, Bohne LJ, Rose RA, Benitez R, Hove-Madsen L, Napolitano C, Hegele RA, Fill M, Sanatani S, Wilde AAM, Roberts JD, Priori SG, Jensen HK, Chen SRW. Cardiac ryanodine receptor calcium release deficiency syndrome. Sci Transl Med. 2021 Feb 3;13(579):eaba7287. doi: 10.1126/scitranslmed.aba7287.
PubMed 33536282Roston TM, Wei J, Guo W, Li Y, Zhong X, Wang R, Estillore JP, Peltenburg PJ, Noguer FRI, Till J, Eckhardt LL, Orland KM, Hamilton R, LaPage MJ, Krahn AD, Tadros R, Vinocur JM, Kallas D, Franciosi S, Roberts JD, Wilde AAM, Jensen HK, Sanatani S, Chen SRW. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiol. 2022 Jan 1;7(1):84-92. doi: 10.1001/jamacardio.2021.4458.
PubMed 34730774Li Y, Wei J, Guo W, Sun B, Estillore JP, Wang R, Yoruk A, Roston TM, Sanatani S, Wilde AAM, Gollob MH, Roberts JD, Tseng ZH, Jensen HK, Chen SRW. Human RyR2 (Ryanodine Receptor 2) Loss-of-Function Mutations: Clinical Phenotypes and In Vitro Characterization. Circ Arrhythm Electrophysiol. 2021 Sep;14(9):e010013. doi: 10.1161/CIRCEP.121.010013. Epub 2021 Sep 1.
PubMed 34546788Ormerod JOM, Ormondroyd E, Li Y, Taylor J, Wei J, Guo W, Wang R, Sarton CNS, McGuire K, Dreau HMP, Taylor JC, Ginks MR, Rajappan K, Chen SRW, Watkins H. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. Circ Genom Precis Med. 2022 Feb;15(1):e003589. doi: 10.1161/CIRCGEN.121.003589. Epub 2021 Dec 24.
PubMed 34949103Ni M, Li Y, Wei J, Song Z, Wang H, Yao J, Chen YX, Belke D, Estillore JP, Wang R, Vallmitjana A, Benitez R, Hove-Madsen L, Feng W, Chen J, Roston TM, Sanatani S, Lehman A, Chen SRW. Increased Ca2+ Transient Underlies RyR2-Related Left Ventricular Noncompaction. Circ Res. 2023 Jul 7;133(2):177-192. doi: 10.1161/CIRCRESAHA.123.322504. Epub 2023 Jun 16.
PubMed 37325910Ni M, Dadon Z, Ormerod JOM, Saenen J, Hoeksema WF, Antiperovitch P, Tadros R, Christiansen MK, Steinberg C, Arnaud M, Tian S, Sun B, Estillore JP, Wang R, Khan HR, Roston TM, Mazzanti A, Giudicessi JR, Siontis KC, Alak A, Acosta JG, Divakara Menon SM, Tan NS, van der Werf C, Nazer B, Vivekanantham H, Pandya T, Cunningham J, Gula LJ, Wong JA, Amit G, Scheinman MM, Krahn AD, Ackerman MJ, Priori SG, Gollob MH, Healey JS, Sacher F, Nof E, Glikson M, Wilde AAM, Watkins H, Jensen HK, Postema PG, Belhassen B, Chen SRW, Roberts JD. A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome. JAMA. 2024 Jul 16;332(3):204-213. doi: 10.1001/jama.2024.8599.
PubMed 38900490
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- International Calcium Release Deficiency Syndrome Registry
- ClinicalTrials.gov ID
- NCT06508164
- Acronym / sponsor ID
- CRDS Registry / 16861
- Conditions
- Calcium Release Deficiency Syndrome
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Population Health Research InstituteUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Study start
- 21 Nov 2024 (actual)
- Primary completion
- 31 Dec 2050 (estimated)
- Study completion
- 31 Dec 2050 (estimated)
- First posted
- 18 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.
Detailed description
Calcium Release Deficiency Syndrome (CRDS) is a recently discovered inherited arrhythmia syndrome that predisposes to malignant ventricular arrhythmias and sudden cardiac death (SCD). The underlying genetic culprit of CRDS is RYR2, which encodes the cardiac ryanodine receptor. In contrast to Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), which stems from pathogenic RYR2 gain-of-function, CRDS manifests secondary to RyR2 loss-of-function. Enrolment into the CRDS registry requires that the putative disease causing RYR2 variant is confirmed to result in a loss-of-function on in vitro functional analysis. Individuals possessing an RYR2 truncating variant or large copy number variant will be eligible for enrolment into a second registry arm. Patients with a suspected CRDS diagnosis whose RYR2 variant is found not to impact function will be entered into a control arm of the registry.
Given its recent discovery, our understanding of CRDS remains in its infancy. The International CRDS registry has been designed to facilitate evaluation of large numbers of CRDS patients and enable robust insights to hopefully improve management of affected patients and families.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 26 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| CRDS | – | –Possesses a rare RYR2 variant characterized to be loss-of-function based on in vitro testing consistent with a CRDS diagnosis |
| Carrier of an RYR2 truncating variant or large copy number variant | – | –Possesses a rare RYR2 truncating variant and/or large copy number variant involving the RYR2 gene. |
| Carrier of a non-functional RYR2 rare variant | – | –Possesses a rare RYR2 variant that is NOT loss-of-function based on in vitro testing and has a clinical phenotype that was considered compatible with CRDS |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The registry will enrol 3 separate cohorts. The primary cohort consists of CRDS cases. A CRDS case is defined as an individual that possesses a rare RYR2 variant proven to be loss-of-function on in vitro analysis. A second cohort consists of individuals that possess a rare RYR2 truncating variant or large copy number variant. The third cohort involves individuals suspected of having CRDS, however in vitro analysis revealed that their rare RYR2 variant did not impact function.
Key inclusion criteria (7 listed)
- Presence of a rare* RYR2 variant that is characterized to be loss-of-function based on in vitro testing#
- RYR2 Truncating and Large CNV Cohort
- Presence of a rare* RYR2 truncating variant and/or large copy number variant involving the RYR2 gene.
- Carriers of a Non-Functional RYR2 variant
- Presence of a rare* RYR2 variant that is characterized to be neither loss- nor gain-of-function based on in vitro testing#
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Malignant Ventricular Arrhythmia
Time frame: 5 years
Composite of malignant syncope, ICD shock, cardiac arrest, and sudden cardiac death
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2026.
- Background: PubMed 33536282Sun B, Yao J, Ni M, Wei J, Zhong X, Guo W, Zhang L, Wang R, Belke D, Chen YX, Lieve KVV, Broendberg AK, Roston TM, Blankoff I, Kammeraad JA, von Alvensleben JC, Lazarte J, Vallmitjana A, Bohne LJ, Rose RA, Benitez R, Hove-Madsen L, Napolitano C, Hegele RA, Fill M, Sanatani S, Wilde AAM, Roberts JD, Priori SG, Jensen HK, Chen SRW. Cardiac ryanodine receptor calcium release deficiency syndrome. Sci Transl Med. 2021 Feb 3;13(579):eaba7287. doi: 10.1126/scitranslmed.aba7287.
- Background: PubMed 34730774Roston TM, Wei J, Guo W, Li Y, Zhong X, Wang R, Estillore JP, Peltenburg PJ, Noguer FRI, Till J, Eckhardt LL, Orland KM, Hamilton R, LaPage MJ, Krahn AD, Tadros R, Vinocur JM, Kallas D, Franciosi S, Roberts JD, Wilde AAM, Jensen HK, Sanatani S, Chen SRW. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiol. 2022 Jan 1;7(1):84-92. doi: 10.1001/jamacardio.2021.4458.
- Background: PubMed 34546788Li Y, Wei J, Guo W, Sun B, Estillore JP, Wang R, Yoruk A, Roston TM, Sanatani S, Wilde AAM, Gollob MH, Roberts JD, Tseng ZH, Jensen HK, Chen SRW. Human RyR2 (Ryanodine Receptor 2) Loss-of-Function Mutations: Clinical Phenotypes and In Vitro Characterization. Circ Arrhythm Electrophysiol. 2021 Sep;14(9):e010013. doi: 10.1161/CIRCEP.121.010013. Epub 2021 Sep 1.
- Background: PubMed 34949103Ormerod JOM, Ormondroyd E, Li Y, Taylor J, Wei J, Guo W, Wang R, Sarton CNS, McGuire K, Dreau HMP, Taylor JC, Ginks MR, Rajappan K, Chen SRW, Watkins H. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. Circ Genom Precis Med. 2022 Feb;15(1):e003589. doi: 10.1161/CIRCGEN.121.003589. Epub 2021 Dec 24.
- Background: PubMed 37325910Ni M, Li Y, Wei J, Song Z, Wang H, Yao J, Chen YX, Belke D, Estillore JP, Wang R, Vallmitjana A, Benitez R, Hove-Madsen L, Feng W, Chen J, Roston TM, Sanatani S, Lehman A, Chen SRW. Increased Ca2+ Transient Underlies RyR2-Related Left Ventricular Noncompaction. Circ Res. 2023 Jul 7;133(2):177-192. doi: 10.1161/CIRCRESAHA.123.322504. Epub 2023 Jun 16.
- Background: PubMed 38900490Ni M, Dadon Z, Ormerod JOM, Saenen J, Hoeksema WF, Antiperovitch P, Tadros R, Christiansen MK, Steinberg C, Arnaud M, Tian S, Sun B, Estillore JP, Wang R, Khan HR, Roston TM, Mazzanti A, Giudicessi JR, Siontis KC, Alak A, Acosta JG, Divakara Menon SM, Tan NS, van der Werf C, Nazer B, Vivekanantham H, Pandya T, Cunningham J, Gula LJ, Wong JA, Amit G, Scheinman MM, Krahn AD, Ackerman MJ, Priori SG, Gollob MH, Healey JS, Sacher F, Nof E, Glikson M, Wilde AAM, Watkins H, Jensen HK, Postema PG, Belhassen B, Chen SRW, Roberts JD. A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome. JAMA. 2024 Jul 16;332(3):204-213. doi: 10.1001/jama.2024.8599.
- Individual participant dataSharing planned: No
Related trials for Calcium Release Deficiency Syndrome
Recruiting
Evaluation of A Clinical Diagnostic Test for CRDS
Calcium Release Deficiency Syndrome (CRDS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Thomas M Roston, MD, PhD study chair
University of British Columbia
Jason D Roberts, MD MAS principal investigator
McMaster University
SR Wayne Chen, PhD principal investigator
University of Calgary
22 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Calcium Release Deficiency Syndrome, run by Population Health Research Institute at 22 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 22 sites in Canada, United States, Belgium, Denmark, United Kingdom and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jason D Roberts, MD MAS (905-297-3479 ext. 40632, crds@phri.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Malignant Ventricular Arrhythmia (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06508164, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.